


Speaker: Michael Saag, MD











38 – HIV Drug Resistance Speaker: Michael Saag, MD





Resistance Testing

- Genotypic resistance test
- Perform test that gives mutations in viral genes
- Phenotypic resistance test
 - $^\circ\,$ Perform test that describes growth of virus in the presence of anti-HIV drugs
- Limitations:
- Cannot detect minority species (< 10% of viral population)

E

- Specific Mutations
- Cross resistance

Easily Tested

 Prevalence of resistance at baseline

Tough to Test

Key Issues in HIV Resistance

- Definition of Phenotypes
- Complex resistance
 patterns
- Genetic Barrier
- Nuances of Resistance
 Relationship between Pk and Pd


Speaker: Michael Saag, MD





HIV Drug Resistance Testing

Current guidelines recommend an <u>HIV genotype</u> as part of screening BEFORE ART is started.

- Following failure of 1st or 2nd regimens, <u>HIV genotype</u> is recommended to use with the history to choose the optimal next regimen.
- Following failure of 3rd and subsequent regimens, both <u>HIV genotype</u> AND <u>HIV phenotype</u> should be sent.
- If there is discordance between genotype and phenotype results, use the geno result (more sensitive).
- NOTE WELL: Resistance mutations accrued from an earlier regimen MAY
 NOT be detected by tests obtained at the time of the current failing
 regimen








Everything You Need to Know About Nucleoside Analog										
Resistance in One Slide!										
Mutation	Selected by	Effects on other NRTIs								
184 V	3TC, FTC	- Loss of susceptibility to 3TC, FTC - ↓ susceptibility to ABC, ddl (clinically insignificant) - Delayed TAMS and † susceptibility to AZT, d4T,TDF								
TAMs	AZT, d4T	- ↓ susceptibility to all NRTIs based on number of TAMs - More resistance with 41/210/215 than 67/70/219 pathway								
151M, 69ins	AZT/ddl, ddl/d4T	- Resistance to all NRTIs - T69ins:TDF resistance								
K65R	TDF, ABC, ddl	- Variable 1 susceptibility to TDF,ABC, ddl (and 3TC, FTC) - ↑ susceptibility to AZT								
74¥	ABC, ddl	- ↓ susceptibility to ABC, ddl - ↑ susceptibility to AZT,TDF								
44D, 1181	AZT, d4T	-Increase NRTI resistance (with 41/210/215 pathway)								

CASE I

- 25 year old man presents with newly diagnosed HIV
- Had an episode c/w acute seroconversion syndrome 4 months ago
- Initial HIV RNA 40,000; CD4 443 cells/ul
- He wants to start ARV therapy

Speaker: Michael Saag, MD



- B. Zidovudine
- Tenofovir
- D. Etravirene
- Emtricitabine


	DRUG			DSENSE [™] S		ILITY	Drian	Sensiti	vity 7	NET ASSESS	MENT	
Generic Name	Brand Name	Fold Change .	Increasing	Drug Susceptibili	P Decreasing	1050	Drug	Phono Sense	Gene Seq			
Abacavir	Ziagen	3.45		H			ABC	Y	Y	Sensitive		
Didanosi	e Videx *	1.25		Delet .			ddl	Y	Y	Sensitive		
Emtricita	sine Emtriva ^{\$}	>MAX		84			FTC	N	N	Reduced Susc.		
😤 Lamivudi	te Epivir	►MAX		54			3TC	N	N	Reduced Susc.		
Stavudin	Zerit	0.79		■ H4		_	d4T	Y	Y	Sensitive	(3)	
Zidovudi	e Retrovir	0.27		64			ZDV	Y	Y	Sensitive	(3)	
Tenofovi	Viread *	0.46		1 H			TEV	Y	Y	Sensitive	(3)	
NRTI N	utations	M184V										
Efavirenz		0.91		141			DLV	Y	Y	Sensitive		
Efavirenz	Sustiva	0.55		1 41			EFV	Y	Y	Sensitive		
Nevirapir		0.53		N			NVP	Y	Y	Sensitive		
NNRTI		none										
III Enfuvirtie		Susceptibi	ity testing for I	Enfuvirtide require	s a separate assi	φ.						
He Clinical Cu Hit Biological/	off asay Cutoff	Cutoff	ausceptibility	Reduces	Susceptibility	Y Evider N Evider	ice of De	rug Ser iduced	Drug	/ Susceptibility		
Virus R	Phication Capacit (Range 20%-49%)	y = 31%		····		virus to repli	cate in t	he abs fidence	ence i	is the ability of the if drug. Range al around RC of wild-type viruses		



CASE 2

- 34 yo woman diagnosed with HIV 10 years ago
- Initially presented with PJPInitial Lab values
- CD4 82 cells/uL
- VL 106,000 c/mL
- Started on TDF / FTC / EFV (FDC)
- Did well for a while, then the regimen failed

	Question #2
\mathcal{U}	The genotype shows an M184V and K65R mutations. Which nRTI drugs would you include? A. ZDV B. TDF C. ddl D. ABC



		DRUG			SETM S	SUSCEPTIBILI		nee of	Net Assessm	hen
	Generic Name		Cutoffs (Lower - Upper		asing Drug Su	10 Decreasing	- Phone	0000		-
	Abacavir		(4.5 - 6.5)	1.79		N H	Y	Y	Sensitive	
	Didanosine		(1.3 - 2.2)	1.54	E1	4	р	N	Partially Sensitive	
	Emtricitabine		(2.5)	4.97		8	N	N	Resistant	
l≅	Lamivudine		(3.5)	5.73		P .	N	N	Resistant	
2	Stavudine		(1.7)	0.85	1 H		Y	Y	Sensitive	
	Zidovudine		(1.9)	0.40	1		Y	Y	Sensitive	2,2
	Tenofovir		(1.4 - 4)	1.74	100	4	P	N	Partially Sensitive	2
	NRTI Mutatie	ms	K65R							
	wer Olinical Cutoff pper Clinical Cutoff	(in bold)	Hype Cust	чилосарбыйу	Sensitive Partaty and Resistant	lonaŭve	Y Eviden P Eviden N Eviden	0 of D 0 e of P 0 e of D	ng Sensitivity amat Dug Sensitivity ng Resistance	


Speaker: Michael Saag, MD

- Non-nucleoside Reverse Transcriptase (NNRTI) Mutations
- <u>K103N</u> is the signature mutation for efavirenz (EFV).
- **<u>Y181C</u>** is the signature mutation for nevirapine (NVP).
- Older NNRTIs, efavirenz and nevirapine, have low genetic barriers (require only I mutation for resistance) and are COMPLETELY cross-resistant to one another.
- Newer NNRTIs, etravirine (ETR), rilpivirine (RPV), and doravirine (DOR) have higher barriers to resistance (require > I mutation for resistance).
- K103N has no effect on etravirine susceptibility.
- Rilpivirine failure is associated with E138K, K101E, and/or
- YI8IC and consequently, resistance to ALL NNRTIs.


C.


CASE 3

- 34 yo woman diagnosed with HIV three years ago
- Initially presented with PJP
- Initial Lab values
 - CD4 82 cells/uL
 - VL 106,000 c/mL
- She was treated with TDF / FTC / ELV/ Cobi (FDC)
- The regimen failed after 12 months




	InSTI	Res	sis	ta	n		9			ta		ons	5	
Bictegravir ²⁶						G 118		138	G 140		148			263
						R		ĸ	S		н			ĸ
Cabotegravir ²⁷	T 66					G 118		E	G 140		Q 148	s 153	N 155	R
Cabotegravir	66 K					118 R		138 A K T	A C R S		148 H K R	F Y	155 H	263 K
						G	F	ε	G		Q		N	R 263
Dolutegravir ²⁸						118 R	121	138 A K T	140 A S		148 H K R		155 H	263 K
	Ţ		E	T			F				S Q		N	R 263
Elvitegravir ²⁹	66 1 A K		92 Q G	97 A			121 Y				147148 G H K R		155 H	263 K
Raltegravir ³⁰		L	92 Q	97			121	E 138	G 140	Y 143	148		N 155	R 263
Kaltegravii		74 M	Q	9/ A			Y	A K	AS	RHC	HKR		135 H	K






Speaker: Michael Saag, MD


	Question #4
\mathcal{U}	Which of the following ARV resistance mutations is most likely in this setting? A. SI47G B. NI55H C. YI43R
	D. E92Q E. K65R




InSTI Resistance Mutations													
Bictegravir ²⁶					G 118		E 138	G 140		143			263
Bictegravir					R		K	S		H			K
	T				G		E	G		0	¢	N	
Cabotegravir ²⁷	66				118		138	140		Q 143	153	N 155	263 K
	ĸ				R		A K T	A C R S		H K R	Ŷ	н	ĸ
					G	F	Ε	G		0		Ν	R
Dolutegravir ²⁸					118	121	138	140		148 H		155	263 K
					ĸ	*	A K T	A S		ĸ			
The face second second second	T		E	T		F			5	Q		N 155	R
Elvitegravir 29	66 		92 Q G	97 A		121			147 G	H K R		н	263 K
Delte en el 1910		L	E	T		F	E	G	Y	Q		N	263
Raltegravir ³⁰		74	92	97 A		121	138 A	140	143	148 H		155	263 K
		-	4				ĸ	A S	R H C	ĸ			-

 CASE 4 34 yo woman diagnosed with HIV 22 years ago Initially presented with PJP Initial Lab values CD4 82 cells/uL VL 106,000 c/mL Has been on multiple regimens over the years





Speaker: Michael Saag, MD



Common Mutations To	Memorize
 M184V/I 	3TC and FTC
M41L, D67N, K70R, L210W, T215Y, K219Q	"TAMS"
4 or more thymidine-analog mutations (TAMS) affect all approve	d nucleosides
 K65R 	tenofovir
• Q151M, 69SSS	multi-NRTI
KI03N retains susceptibility to etravirine	EFV (and NVP)
• YI8IC	NVP and other NNRTI
• EI38K, KI0IE	RPV and other NNRTI
• 150L	ATV
• N155H, Q148H/R/K	RAL and EVG
• Y143C	RAL
• R263K	DTG



Summary

- High concern about resistance testing on Board Exams
- Difficult to create test questions that do not require complex interpretation, have a single best answer, or are not 'multiple true-false'
- Knowing common mutations and their role is a good way to prepare for the exam

